Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimer's disease

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 19, 2009, Pages 5703-5707

  Helal, Christopher J ^a   Kang, Zhijun ^a   Lucas, John C ^a   Gant, Thomas ^a   Ahlijanian, Michael K ^a   Schachter, Joel B ^a   Richter, Karl E G ^a   Cook, James M ^a   Menniti, Frank S ^a   Kelly, Kristin ^a   Mente, Scot ^a   Pandit, Jay ^a   Hosea, Natalie ^a  

^a PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Cyclin dependent kinase 2; Cyclin dependent kinase 5; p25

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLOBUTANE DERIVATIVE; IMIDAZOLE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN P25;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ALZHEIMER DISEASE; ANIMALS; BINDING SITES; CACO-2 CELLS; CRYSTALLOGRAPHY, X-RAY; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 5; DRUG DESIGN; HUMANS; IMIDAZOLES; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 69949102162     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.08.019     Document Type: Article

References (30)

1. McInnes C. Drug Discovery Today 13 (2008) 875
2. Lau L.-F., Schachter J.B., Seymour P.A., and Sanner M.A. Curr. Top. Med. Chem. 2 (2002) 395
3. Lau L.-F., Seymour P.A., Sanner M.A., and Schachter J.B. J. Mol. Neurosci. 19 (2002) 267
4. Cruz J.C., and Tsai L.-H. Trends Mol. Med. 10 (2004) 452
5. Churcher I. Curr. Top. Med. Chem. 6 (2006) 579
6. Wei F.-Y., and Tomizawa K. Mini-Rev. Med. Chem. 7 (2007) 1070
7. Pareek T.K., and Kulkarni A.B. Cell Cycle 5 (2006) 585
8. Slevin M., and Krupinski J. Curr. Opin. Pharmacol. 9 (2009) 119
9. For recent reviews of cdk5/p25 inhibitors, see:. Glicksman M.A., Cuny G.D., Liu M., Dobson B., Auerbach K., Stein R.L., and Kosik K.S. Curr. Alzheimer Res. 4 (2007) 547
10. Sridhar J., Akula N., and Pattabiraman N. AAPS J. 8 (2006) Article 25
11. Helal C.J., Sanner M.A., Cooper C.B., Gant T., Adam M., Lucas J.C., Kang Z., Kupchinsky S., Ahlijanian M.K., Tate B., Menniti F.S., Kelly K., and Peterson M. Bioorg. Med. Chem. Lett. 14 (2004) 5521
12. Kalgutkar A.S., Driscoll J., Zhao S.X., Walker G.S., Shepard R.M., Soglia J.R., Atherton J., Yu L., Mutlib A.E., Munchhof M.J., Reiter L.A., Jones C.S., Doty J.L., Trevena K.A., Shaffer C.L., and Ripp S.L. Chem. Res. Toxicol. 20 (2007) 1954
13. For synthesis details, see Supplementary data and Ahlijanian, M. K.; Cooper, C. B.; Helal, C. J.; Lau, L.-F.; Menniti, F. S.; Sanner, M. A.; Seymour, P. A.; Villalobos, A. WO 2002010141 A1; Chem. Abstr. 2002, 107322.
14. Bulusu S., Damavarapu R., Autera J.R., Behrens Jr. R., Minier L.M., Villanueva J., Jayasuriya K., and Axenrod T. J. Phys. Chem. 99 (1995) 5009
15. Thermodynamic testing showed that 3 was a highly energetic substance with the potential for self-heating from 35 °C that could lead to explosion. This material should be used in small amounts and stored in a freezer. Solutions of 3 in methanol (1 M or less) were found to have reduced explosive potential and thus reactions at 23 °C were deemed to be of reduced risk. Nonetheless, appropriate safety procedures should be strictly observed when handling this compound.
16. 50 was determined from a six-point dose-response curve run in triplicate.
17. m for the respective kinase: MKK1, JNK, p38, p38α, p38γ, p38δ, MAPKAP-K2, MSK1, PKCα, PDK1, PKBα, SGK, P70SK6, GSK3β, ROCKII, AMPK, CK2, MAPKAP-K1b, MAPK1, PHK.
18. The cdk5 homology model was built on in-house X-ray structures of cdk2-inhibitor complexes, and due to the high homology between the two, is very similar to the cdk2 X-ray structures themselves. Retrospectively, comparing the homology model to that of the reported cdk5-inhibitor complexes (Mapelli, M.; Massimiliano, L.; Crovace, C.; Seeliger, M. A.; Tsai, L.-H.; Meijer, L.; Musacchio, A. J. Med. Chem., 2005, 48, 671) reveals nearly identical residue-by-residue similarity.
19. Helal C.J., Kang Z.K., Lucas J.C., and Bohall B.R. Org. Lett. 6 (2004) 1853
20. See Supplementary data for representative experimental conditions, yields, and spectral data.
21. Human recombinant cdk2 was expressed, purified and crystallized as described previously (Brown, N. R.; Noble, M. E.; Lawrie, A. M.; Morris, M. C.; Tunnah, P.; Divita, G.; Johnson, L. N.; Endicott, J. A. J. Biol. Chem. 1999, 274, 8746). Structures were derived from cdk2 crystals that were soaked in solutions containing inhibitor.
22. The X-ray crystal structures have been placed in the PDB with code numbers 3IGG (Fig. 2) and 3IG7 (Fig. 3).
23. m for the respective kinase: ABL, CK1δ, GSK3β, IKKi, IKKβ, LCK, MAPKAP-K2, p38α, PKA, PKCζ, CDK2/Cyclin A, CHK1, CHK2, FGFR1, MET, PAK4, PDK1, PIM2, SRC, CK-II, EGFR, TRK-A, VEGFR-2, AKT1, INSR, Aurora-A, MAPK1/ERK2, SGK, BTK, TAOK3, CAMK1, ECK, PKCβ, CLK1, MARK1, NEK2, JAK3, MYLK2, MAP3K9, MASK, S6K-T389E-D3E, ROCK1, SYK, MST2, CDK6/Cyclin D3, MAP4K4, MEK1, TGFR-1, BRAF.
24. Gong C.-X., and Iqbal K. Curr. Med. Chem. 15 (2008) 2321
25. Engmann O., and Giese K.P. Front. Mol. Neurosci. 2 (2009) 2
26. Mazanetx M.P., and Fischer P.M. Nat. Rev. Drug Discovery 6 (2007) 464
27. cdk5 whole cell assay: A tetracycline-regulated expression system was used to produce a stable CHO cell line carrying inducible expression of human Cdk5, P25 and tau driven from modified pRevTRE Tet-Off vectors containing distinct antibiotic resistance genes. The cell line was maintained in the uninduced state in media containing doxycycline and then transgene induction was initiated by removal of doxycycline from the medium for 24 h. Following full induction of CDK5, P25, and tau, cells were incubated for 2 h with test compounds before lysis. Phosphorylated tau was measured in detergent-soluble extracts of cells using AlphaLISA (Perkin-Elmer). A capture antibody to total tau (HT7, Pierce) was conjugated to Acceptor beads, and a biotinylated phospho-epitope specific detection antibody (AT8, Pierce) was bound to streptavidin donor beads (Perkin-Elmer).
28. +.
29. Shinkel A.H., Wagenaar E., Mol C.A., and van Deemter L. J. Clin. Invest. 97 (1996) 2517
30. For an analysis of commercial drugs' brain penetration in wild type versus MDR1A/1B knockout mice, see:. Doran A., et al. Drug Metab. Dispos. 33 (2005) 165